Added to YB: 2026-06-12
Pitch date: 2026-06-10
MRK [neutral]
Merck & Co., Inc.
+0.6%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$294.1B
Pitch Price
$120.04
Price Target
N/A
Dividend
2.85%
EV/EBITDA
11.28
P/E
33.30
EV/Sales
5.13
Sector
Pharmaceuticals
Category
growth
GS Healthcare Conference – Recap part 1 (Day 2) - Merck & Co., Inc.
MRK (overview): Merck $104.25. M&A Score 68, Growth Score 85. Large-cap pipeline acceleration play targeting $70B pipeline, ~50% de-risked by end 2026. Key assets: SAC-TMT TROP2 ADC (17 Ph3 trials), PD-1/VEGF bispecific, KRAS franchise, Moderna mRNA INT, TL-1A UC readout Aug-Sept, HIV long-acting. Multi-program, not single-catalyst.
Read full article (1 min)